Medicenna Announces Management - GuruFocus.com
GuruFocus Article or News written by GuruFocusNews and the topic is about:
Source: gurufocus.com
📰 Mann Muhsin News
Mann Muhsin News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mann Muhsin. Real-time updates on events, politics, business and more.
Medicenna Announces Management Change and Appoints Experienced Development Advisory Committee
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
Medicenna Announces Management Change and Appoints
Phase 1/2 ABILITY study of MDNA11 remains on track for an update on additional safety pharmacokinetic (PK), and pharmacodynamic (PD) data in low-dose...
Source: globenewswire.com
Medicenna Reports First Quarter Fiscal 2022 Financial Results and Operational Highlights
— Phase 1/2 ABILITY Study of MDNA11 in patients with advanced solid tumors remains on track for initiation in the third quarter of calendar 2021
United States United Kingdom Elizabeth Williams Superkine Immunotherapies Mann Muhsin Human Research Ethics Committee
Source: leaderpost.com
Chutes & Ladders—Another Novartis exec answers the biotech call, this time for gene therapy startup Tevard
Novartis has lost another NIBR exec to the call of biotech. Blueprint Medicines has added another BMS vet to its roster. And Iovance quietly announced its CEO's departure Wednesday.
Source: fiercebiotech.com
BioSpace Movers & Shakers, May 14
Published: May 13, 2021 By Alex Keown Akouos, Inc. – Kathy Reape was named chief development officer of Boston-based Akouos. Reape most recently served as chief medical officer at Spark Therapeutics where she oversaw clinical development, pharmacovigilance, and medical affairs activities. Reape was a key member of the team responsible for the development and commercialization of Luxturna, the first FDA-approved in vivo gene therapy approved for an inherited retinal disease caused by m...
Source: biospace.com